Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes the vascular endothelial growth factor-stimulated MAPKs and downstream effectors AP-1 and CREB in mouse mesangial cells
- 19 May 2012
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 368 (1-2) , 47-59
Abstract
Along with its natriuretic, diuretic, and vasodilatory properties, atrial natriuretic peptide (ANP), and its guanylyl cyclase/natriuretic peptide receptor-A (GC-A/NPRA) exhibit an inhibitory effect on cell growth and proliferation. However, the signaling pathways mediating this inhibition are not well understood. The objective of this study was to determine the effect of ANP–NPRA system on mitogen-activated protein kinases (MAPKs) and the downstream proliferative transcription factors involving activating protein-1 (AP-1) and cAMP-response element binding protein (CREB) in agonist-stimulated mouse mesangial cells (MMCs). We found that ANP inhibited vascular endothelial growth factor (VEGF)-stimulated phosphorylation of MAPKs (Erk1, Erk2, JNK, and p38), to a greater extent in NPRA-transfected cells (50–60 %) relative to vector-transfected cells (25–30 %). The analyses of the phosphorylated transcription factors revealed that ANP inhibited VEGF-stimulated activation of CREB, and the AP-1 subunits (c-jun and c-fos). Gel shift assays demonstrated that ANP inhibited VEGF-stimulated AP-1 and CREB DNA-binding ability by 67 and 62 %, respectively. The addition of the protein kinase G (PKG) inhibitor, KT-5823, restored the VEGF-stimulated activation of MAPKs, AP-1, and CREB, demonstrating the integral role of cGMP/PKG signaling in NPRA-mediated effects. Our results delineate the underlying mechanisms through which ANP-NPRA system exerts an inhibitory effect on MAPKs and down-stream effector molecules, AP-1, and CREB, critical for cell growth and proliferation.Keywords
This publication has 52 references indexed in Scilit:
- A cardiac pathway of cyclic GMP-independent signaling of guanylyl cyclase A, the receptor for atrial natriuretic peptideProceedings of the National Academy of Sciences, 2011
- The functional genomics of guanylyl cyclase/natriuretic peptide receptor‐A: Perspectives and paradigmsThe FEBS Journal, 2011
- Platelet-derived Growth Factor Differentially Regulates the Expression and Post-translational Modification of Versican by Arterial Smooth Muscle Cells through Distinct Protein Kinase C and Extracellular Signal-regulated Kinase PathwaysJournal of Biological Chemistry, 2010
- MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targetsClinical Science, 2008
- Emerging roles of natriuretic peptides and their receptors in pathophysiology of hypertension and cardiovascular regulationJournal of the American Society of Hypertension, 2008
- Role of natriuretic peptide signaling in modulating asthma and inflammationThis article is one of a selection of papers published in the Special Issue on Recent Advances in Asthma Research.Canadian Journal of Physiology and Pharmacology, 2007
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Rescue of CH31 B Cells from Antigen Receptor-Induced Apoptosis by Inhibition of p38 MAPKBiochemical and Biophysical Research Communications, 2000
- Natriuretic Peptide Receptor-A Negatively Regulates Mitogen-Activated Protein Kinase and Proliferation of Mesangial Cells: Role of cGMP-Dependent Protein KinaseBiochemical and Biophysical Research Communications, 2000
- A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in ratsLife Sciences, 1981